Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Massachusetts General Hospital
Systemic amyloidosis is a progressive disease leading to organ failure and death. Treatment has improved survival with stem-cell transplantation. Unfortunately, patients with amyloidosis and severe heart failure are not eligible for stem-cell transplantation.
The average rate of survival for patients with amyloidosis who receive a heart transplant is decreased.
Previous trials have raised the possibility that survival may be increased in patients with amyloidosis, if chemotherapy and stem-cell transplantation is performed after a heart transplant.
We plan to review data of patients with amyloidosis and heart failure who were being evaluated for a heart transplant.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with amyloidosis
NYHA class III or IV heart failure
Patients undergoing heart transplant evaluation
Patients less than 18 years of age
You may not be if
Patients who have unstable pulse and blood pressure